|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Johnson_&_Johnson
2011
$2.4 billion
|
|
gptkbp:awards
|
gptkb:European_Vaccine_Award
Best Vaccine Company Award
Innovative_Biopharmaceutical_Company_Award
|
|
gptkbp:CEO
|
gptkb:Johan_van_Hoof
gptkb:Ron_Cohen
|
|
gptkbp:clinicalTrials
|
multiple ongoing
|
|
gptkbp:employees
|
approximately 500
|
|
gptkbp:established
|
2000
|
|
gptkbp:focus
|
vaccine development
|
|
gptkbp:founded
|
2000
|
|
gptkbp:headCoach
|
500+
|
|
gptkbp:headquarters
|
gptkb:Switzerland
gptkb:Leiden,_Netherlands
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Crucell Switzerland AG
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:investmentFocus
|
public shareholders
|
|
gptkbp:keyPeople
|
gptkb:Johan_van_Hoof
gptkb:Jaap_Goudsmit
gptkb:Ron_Cohen
|
|
gptkbp:market
|
$2 billion (2010)
|
|
gptkbp:mayHave
|
gptkb:Jaap_Goudsmit
|
|
gptkbp:netIncome
|
$10 million (2010)
|
|
gptkbp:notableEvent
|
AdVac technology
PER.C6 cell line
Quinvaxem
|
|
gptkbp:partnerships
|
gptkb:GAVI_Alliance
gptkb:European_Commission
various universities
WHO
|
|
gptkbp:patentCitation
|
numerous vaccine patents
|
|
gptkbp:products
|
vaccines
therapeutics
|
|
gptkbp:researchAndDevelopment
|
$50 million (2010)
|
|
gptkbp:researchFocus
|
biologics
infectious diseases
|
|
gptkbp:revenue
|
$100 million (2010)
|
|
gptkbp:subsidiary
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
Euronext Amsterdam
|
|
gptkbp:type
|
public company
|
|
gptkbp:website
|
www.crucell.com
|